Table 1.
Basic demographic and clinical characteristics of psoriatic arthritis (PsA) and psoriasis (PsO) groups.
| Variable | PsA group (N = 46) |
PsO group (N = 42) |
|---|---|---|
| Male : female ratio | 24 : 22 | 31 : 11 |
| Age (mean ± SD; years) | 54.35 ± 11.87 | 45.60 ± 15.72 |
| BMI (mean ± SD; kg/m2) | 29.38 ± 6.41 | 28.86 ± 9.80 |
| Current smokers (%) | 20 | 12 |
| Age at diagnosis of PsO (mean ± SD; years) | 38.91 ± 14.47 | 28.84 ± 15.82 |
| Age at diagnosis of PsA (mean ± SD; years) | 45.26 ± 13.80 | — |
| Disease course severity (mild : moderate to severe)• | 0 : 46 | 6 : 36 |
| Psoriasis guttata (%) | 4 | 20 |
| Arthritis mutilans (%) | 2 | — |
| Axial arthritis (%) | 17 | — |
| Distal arthritis (%) | 4 | — |
| Asymmetrical oligoarthritis (%) | 54 | — |
| Symmetrical polyarthritis (%) | 43 | — |
| Therapy | ||
| Received MTX therapy (%) | 85 | 57 |
| Received systemic steroid treatment (%) |
13 | 2 |
| Received 311 nm NB-UVB therapy (%) |
7 | 38 |
| Received PUVA therapy (%) | 2 | 31 |
| Received biological therapy (%) | 13 | 52 |
PsO: psoriasis vulgaris, PsA: psoriatic arthritis, BMI: body mass index, MTX: methotrexate, PUVA: psoralen + ultraviolet A, 311 nm NB-UVB: 311-nanometer narrow-band ultraviolet B. Symmetrical arthritis: bilateral arthritis with a frequency of >50%.
•Patients previously or currently treated with DMARDs, systemic therapy or full-body phototherapy were regarded as “moderate-to-severe” patients, whereas the others were considered to exhibit a “mild” disease course.